At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 425 enrolled
Drug / intervention
Pregabalin +3 moredrug
Likely dose
Pregabalin 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double Blind Multi Center Dose Ranging Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo In The Adjunctive Treatment Of Post Surgical Pain After Primary Inguinal Hernia Repair
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Oct 30, 2007·Updated Jan 25, 2021
In Brief
A Phase 3 clinical trial evaluating Pregabalin and placebo for Pain, Postoperative and Hernia, Inguinal. Completed, enrolled 425 participants across 42 sites in 6 countries.
Detailed Summary
The purpose of this study is to test whether pregabalin added to the standard of care with dosing starting preoperatively and continuing for 1 week post surgery will decrease the intensity of acute post-operative pain following inguinal hernia repair.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain, Postoperative, Hernia, Inguinal
CountriesAustralia, Canada, India, Spain, Sweden, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2007
Enrollment StartJan 2008
Primary CompletionJun 2009
Study CompletionSep 2009
TodayJul 2026
First PostedOct 30, 2007
Enrollment StartJan 1, 2008
Primary CompletionJun 1, 2009
Study CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 18.7 years ago
Interventions
Pregabalindrug
150 mg BID
placebodrug
Placebo
Pregabalindrug
75 mg BID
Pregabalindrug
25 mg BID